SCOPUS 정보 검색 플랫폼

Volumn 195, Issue 3, 2010, Pages 563-566

FDA statement on relationship between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures: A considered opinion

(2) Rogers, Lee F a Taljanovic, Mihra a

a UNIVERSITY OF ARIZONA (United States)

Author keywords

Atypical femoral fractures; Bisphosphonates; Insufficiency fractures of the femur; Stress fractures of the femur

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

BONE MINERALIZATION; CHRONIC DRUG ADMINISTRATION; FALLING; FEMALE; FEMUR SHAFT FRACTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; OPEN REDUCTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; CHEMICALLY INDUCED; FEMORAL FRACTURES; RISK FACTOR; UNITED STATES;

DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956812593 PISSN: 0361803X EISSN: 15463141 Source Type: Journal
DOI: 10.2214/AJR.10.4906 Document Type: Note

Times cited : (13)

References (12)

1
- 34147179587
- Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution
- DOI 10.1302/0301-620X.89B3.18146
- Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89:349-353 (Pubitemid 46563912)
- (2007) Journal of Bone and Joint Surgery - Series B , vol.89 , Issue.3 , pp. 349-353
- Goh, S.-K.¹ Yang, K.Y.² Koh, J.S.B.³ Wong, M.K.⁴ Chua, S.Y.⁵ Chua, D.T.C.⁶ Howe, T.S.⁷

2
- 38749135807
- An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?
- Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39:224-231
- (2008) Injury , vol.39 , pp. 224-231
- Kwek, E.B.¹ Goh, S.K.² Koh, J.S.³ Png, M.A.⁴ Howe, T.S.⁵

3
- 40949099444
- More on atypical fractures of the femoral diaphysis in post-menopausal women taking alendronate
- Lenart BA, Lorich DG, Lane JM. More on atypical fractures of the femoral diaphysis in post-menopausal women taking alendronate. N Engl J Med 2008; 358:1304-1306
- (2008) N Engl J Med , vol.358 , pp. 1304-1306
- Lenart, B.A.¹ Lorich, D.G.² Lane, J.M.³

4
- 67650468390
- Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study
- Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20:1353-1362
- (2009) Osteoporos Int , vol.20 , pp. 1353-1362
- Lenart, B.A.¹ Neviaser, A.S.² Lyman, S.³

5
- 77950623902
- Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy
- Porrino JA, Kohl CA, Taljanovic M, Rogers LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR 2010; 194:1061-1064
- (2010) AJR , vol.194 , pp. 1061-1064
- Porrino, J.A.¹ Kohl, C.A.² Taljanovic, M.³ Rogers, L.F.⁴

6
- 74249108694
- Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate
- Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80:413-415
- (2009) Acta Orthop , vol.80 , pp. 413-415
- Schilcher, J.¹ Aspenberg, P.²

7
- 77956800262
- Fosamax drug could become next Merck woe
- April 12
- Carreyrou J. Fosamax drug could become next Merck woe. Wall Street Journal Eastern Edition April 12, 2006:B1
- (2006) Wall Street Journal Eastern Edition
- Carreyrou, J.¹

8
- 66349094278
- Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study
- Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24:1095-1102
- (2009) J Bone Miner Res , vol.24 , pp. 1095-1102
- Abrahamsen, B.¹ Eiken, P.² Eastell, R.³

9
- 77952314262
- Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur
- Accessed June 1, 2010
- Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362:1761- 1771 www.nejm.org. Accessed June 1, 2010
- (2010) N Engl J Med , vol.362 , pp. 1761-1771
- Black, D.M.¹ Kelly, M.P.² Genant, H.K.³

10
- 77953522453
- Website Published March 10, Accessed June 1, 2010
- U.S. Food and Drug Administration Website. FDA drug safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. www.fda.gov. Published March 10, 2010. Accessed June 1, 2010
- (2010) FDA Drug Safety Communication: Ongoing Safety Review of Oral Bisphosphonates and Atypical Subtrochanteric Femur Fractures

11
- 77952307943
- Evolving data about subtrochanteric fractures and bisphosphonates
- Accessed June 1, 2010
- Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010; 362:1825-1827 www.nejm.org. Accessed June 1, 2010
- (2010) N Engl J Med , vol.362 , pp. 1825-1827
- Shane, E.¹

12
- 77953269616
- Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: Imaging features
- Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR 2010; 194:1581-1586
- (2010) AJR , vol.194 , pp. 1581-1586
- Chan, S.S.¹ Rosenberg, Z.S.² Chan, K.³ Capeci, C.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.